rabusertib (LY 2603618)

News alerts, weekly reports and conference planners

Company:

Eli Lilly

Drug class:

Chk1 inhibitor

Related drugs:

TP53 mutation + KRAS mutation	Colon Cancer	TP53 mutation + KRAS mutation	Colon Cancer	LY 2603618 Sensitive: D – Preclinical LY 2603618 Sensitive : D	LY 2603618 Sensitive: D – Preclinical LY 2603618 Sensitive : D
ER positive	Estrogen Receptor Positive Breast Cancer	ER positive	Estrogen Receptor Positive Breast Cancer	LY 2603618 Sensitive: D – Preclinical LY 2603618 Sensitive : D	LY 2603618 Sensitive: D – Preclinical LY 2603618 Sensitive : D

Associations
(2)